FLAVONE OXIDATION DERIVATIVES ACT AS INHIBITORS OF AMYLOID-BETA AGGREGATION

Andrius Sakalauskas1, Vytautas Smirnovas1

1 Institute of Biotechnology, Life Sciences Center, Vilnius University, Lithuania

[email protected]

Protein accumulation into highly dense structure aggregates is associated with multiple neurodegenerative disorders [1]. Alzheimer's disease (AD) was recognized to be the most prevalent condition that affects over 35 million people worldwide and is projected to increase up to 76 million by 2030 [2]. Typically, Alzheimer's disease onset at the age of 60 or later, with leading symptoms of progressive decline in memory and other distinct cognitive capabilities [3]. The pathology of this disease is linked to the aggregation of amyloid-beta ($A\beta$) and the formation of Tau neurofibrillary tangles. $A\beta$ aggregates are found at the very early stage of the disease, thus the inhibition of this peptide formation and aggregation has profound attention of scientists [4]. Over the years, various compounds were suggested for treatment, however, the effort to find disease-modifying drugs were not rewarding leaving more than 99.5% of clinical trial unsuccessful [5]. Yet, in this research, we focus on the flavones as the potential inhibitors of $A\beta$ aggregation. Flavones are natural antioxidants and exhibit neuroprotective and anti-inflammatory effects. The flavones belong to the group of acetylcholinesterase inhibitors, which is shown to have the best positive effect on the treatment of AD symptoms [6]. Although many protein aggregation experiments in vitro using flavone derivates show positive results, the in vivo results are not flattering. This may be related to a different oxidation mechanism at physiological conditions in vivo and in vitro leading to environmentally distinct oxidation products [7], [8].

In this study, we show the link between flavone hydroxy-groups position and the oxidation derivatives that possess $A\beta$ and insulin amyloid aggregation inhibition effect (Fig. 1). The insulin amyloid aggregation was added to this research to analyze flavone inhibition potential at the conditions where auto-oxidation does not occur, thus both non-oxidized and oxidized flavone particles were tested. The absorbance spectrum data reveal that not all tested flavones undergo auto-oxidation at the experimental conditions. The $A\beta$ and insulin aggregation kinetic data show the extreme change of aggregation halftime after compound auto-oxidation. In addition, the atomic force microscopy images display the morphology of the fibrils formed during the experiment.

Figure 1
Fig. 1. Amyloid-Beta aggregation is inhibited by the flavone auto-odixation derivatives

[1] M. Rekatsina, A. Paladini, A. Piroli, P. Zis, J. V. Pergolizzi, and G. Varrassi, "Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A Narrative Review," Adv. Ther., vol. 37, no. 1, pp. 113-139, 2020.

[2] World Health Organization, "Dementia Fact Sheet," WHO, 2020. https://www.who.int/news-room/fact-sheets/detail/dementia.

[3] M. Tanveer et al., “Machine learning techniques for the diagnosis of alzheimer's disease: A review," ACM Trans. Multimed. Comput. Commun. Appl., vol. 16, no. 1s, 2020.

[4] A. Anand, A. A. Patience, N. Sharma, and N. Khurana, "The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review," Eur. J. Pharmacol., vol. 815, no. August, pp. 364-375, 2017.

[5] D. Mehta, R. Jackson, G. Paul, J. Shi, and M. Sabbagh, "Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015," Expert Opin. Investig. Drugs, vol. 26, no. 6, pp. 735-739, 2017.

[6] I. Uriarte-Pueyo and M. I. Calvo, "Flavonoids as Acetylcholinesterase Inhibitors," Curr. Med. Chem., vol. 18, no. 34, pp. 5289-5302, 2011.

[7] H. Nagayoshi et al., "Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes," Chem. Res. Toxicol., vol. 32, no. 6, pp. 1268–1280, 2019.

[8] T. Sneideris et al., "The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG," Biomolecules, vol. 9, no. 12, p. 855, Dec. 2019.